$MODD

Modular Medical, Inc.

Modular Medical develops and commercializes insulin pumps for people with diabetes who require daily insulin, including people with type 1 and type 2 diabetes. Its Pivot is a tubeless, removable patch pump with a reusable pump component and disposable cartridge and infusion set. The system delivers continuous basal insulin and user-administered bolus doses, and can connect to phone software. Modular Medical announced commercial availability of Pivot in the United States in June 2026 and commenced initial shipments. It does not intend to commercialize its MODD1 pump. The company makes insulin pumps and related components, including cartridges and baseplates, and purchases infusion sets from third parties. Phillips Medisize performs manufacturing operations. Modular Medical plans to sell Pivot through distributors and a small direct sales force, and offers patient education through PivotPump.com. The company is headquartered in San Diego, California.

No enriched coverage for $MODD in the last 7 days.

No SEC Form 4 filings for $MODD in the last 30 days.

See all $MODD insider activity →
Low

Modular Medical, Inc. (MODD): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Modular Medical, Inc. (MODD) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On October 26, 2026, Duane DeSisto resigned from the board of directors of Modular Medical, Inc. (the “Company”), effective

Modular Medical, Inc. (MODD) Gets Positive ISO 13485 Decision Toward Certification

Modular Medical (MODD) received a positive ISO 13485:2016 decision, a step toward certification. The company aims for a 2027 CE Mark submission for its Pivot tubeless patch pump under EU MDR. This milestone supports its EU launch plan, with certification and CE Mark expected to enable distribution and revenue.

Modular Medical launches digital tools for insulin pump training

Modular Medical (NASDAQ:MODD) launched digital tools for insulin pump training, developed with Relevate Health Games. The resources, not part of FDA-required training, aim to familiarize patients with Pivot tubeless patch pump before formal training. The tools include a virtual walkthrough and a module in the Level One diabetes game, downloaded over 53,000 times. The company is preparing for the full commercial launch of its Pivot pump.

MODD sentiment & insider activity

Recent MODD coverage spans financial news, market movers and corporate actions.

What's driving MODD

AlphAI scores every news story that mentions MODD with an AI model for sentiment and relevance, and aggregates insider trades from Modular Medical, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $MODD

Score
$MODDLowExec change· resigned

Modular Medical, Inc. (MODD): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Modular Medical, Inc. (MODD) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On October 26, 2026, Duane DeSisto resigned from the board of directors of Modular Medical, Inc. (the “Company”), effective

Modular Medical launches digital tools for insulin pump training

Modular Medical (NASDAQ:MODD) launched digital tools for insulin pump training, developed with Relevate Health Games. The resources, not part of FDA-required training, aim to familiarize patients with Pivot tubeless patch pump before formal training. The tools include a virtual walkthrough and a module in the Level One diabetes game, downloaded over 53,000 times. The company is preparing for the full commercial launch of its Pivot pump.

$MODDLowExec change· resigned

Modular Medical, Inc. (MODD): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Modular Medical, Inc. (MODD) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On September 25, 2026, Jeffrey Goldberg provided written notice to the chair of the nominating and governance committee (th

Modular Medical, Inc.: Modular Medical Announces Contract with National U.S. Pharmacy Benefit Manager, Expanding Access to Pivot Tubeless Patch Pump

Modular Medical, Inc. (NASDAQ:MODD) announced a contract with a national U.S. pharmacy benefit manager (PBM), expanding access to its Pivot tubeless patch pump for diabetes patients. The company believes this partnership will broaden patient access and validate its insulin delivery system. Modular Medical aims to simplify diabetes management with its innovative medical device.

6 Biotech Stocks In Focus: Modular Medical, Galmed, Pro-Dex, Connect Biopharma & More

Modular Medical (MODD) received FDA clearance for software enhancements to its Pivot insulin pump, planning a commercial launch in October 2026. Galmed (GLMD) shareholders approved all proposals, including a name change. Pro-Dex (PDEX) reported strong Q4 results with 17% sales growth. eHealth (EHTH) saw after-hours gains despite a Q2 net loss. Connect Biopharma (CNTB) will present at a conference and report Phase 2 trial results. AVITA Medical (RCEL) expects full-year revenue of $86M-$89M.

6 After-Hours Healthcare Gainers: Universe Pharma, BioAffinity, Modular Medical, Telix Pharma & More

Universe Pharmaceuticals (UPC) rose 34.89% after-hours due to multiple Schedule 13G filings. BioAffinity (BIAF) explores new uses for its CyPath Lung test, up 3%. Modular Medical (MODD) gained 7% after announcing a product launch. MAIA (MAIA) rose 6% following an insider purchase. Telix (TLX) completed a Phase 3 study, up 2.21%. aTyr Pharma (ATYR) awaits FDA response, up 4%.

After-hours Gainers: HOWL Jumps 90%, MODD To Begin Pivot Pump Rollout, BIVI Awaits Long COVID Data

Werewolf Therapeutics (HOWL) rose 90% in after-hours trading, with key clinical trials ongoing. GeoVax (GOVX) gained 12.66%, preparing for a pivotal Phase 3 study. Greenwich LifeSciences (GLSI) increased 6.27%, extending share lock-up. Modular Medical (MODD) up 7.87%, planning Pivot pump rollout. Ovid Therapeutics (OVID) rose 6.93%, with multiple clinical milestones. BioVie (BIVI) up 4.84%, awaiting long COVID data.

Modular Medical, Inc.: Modular Medical and IMO Health Launch Strategic Pilot to Enable Real Time Insulin Pump Patient Identification Into Electronic Health Records

Modular Medical (NASDAQ:MODD) said it is running a strategic pilot with IMO Health to build an EHR-based, terminology-powered algorithm that identifies diabetes patients likely to benefit from its Pivot insulin pump. The pilot will use clinician-guided phenotypes and IMO Health terminology value sets, supporting a planned Pivot commercial launch in Q4 2026.

Related tickers